The WHO Recognizes NOX Inhibitors as New Therapeutic Class and Approves Setanaxib for GKT831

Ads

You May Also Like

Loxo Oncology to Present at Cowen and Company 37th Annual Health Care Conference

STAMFORD, Conn., March 01, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company ...

Tyme Announces First Site Open for its Phase II Trial with SM-88 in Pancreatic Cancer

NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the ...

Momenta Pharmaceuticals to Webcast Presentation at the 34th Annual J. P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology ...